Dave, are you pinning your vote decision on the milestones, or the share price? From your comments it sounds like you're focusing more on share price. I am not using the share price as a decision point in my vote because I can't be sure how the market will respond to news of milestones being completed. I also remind myself of Gerald's statement that if the market conditions aren't where they expect them to be to uplist, they will postpone the uplist until market conditions are more favorable. This negates the suggestion some make that the company will do a massive RS to uplist if the price is low. Not gonna happen, according to Gerald.
Isn't it a bit premature to start talking about postponing the SHM? We still have 19 days for developments to be announced. Let's see what unfolds.
I've already voted YES with my shares, and have the option to recast my vote if I'm given sufficient reason to change my outlook. I seriously doubt that will happen, because I believe the additional shares are to support a spinoff of the diagnostics division, and that likely won't happen until sometime later next year... but the preparation will already have been made with the additional authorized shares to support the spinoff.
(0)
(0)
Amarantus Bioscience Holdings (AMBS) Stock Research Links